Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status

• Krastan B. Blagoev ,

  * E-mail: krastanb@gmail.com

  Affiliations Physics of Living Systems, National Science Foundation, Arlington, Virginia, United States of America, Department of Biophysics, Johns Hopkins University, Baltimore, Maryland, United States of America

  ⨯
• Julia Wilkerson,

  Affiliation Medical Oncology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, United States of America

  ⨯
• Mauricio Burotto,

  Affiliation Departamento de Oncologia, Clinica Alemana de Santiago, Santiago, Chile

  ⨯
• Chul Kim,

  Affiliation Medical Oncology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, United States of America

  ⨯
• Edward Espinal-Domínguez,

  Affiliation Departamento de Oncologia Medica, Gregorio Marañon University Hospital, Madrid, Spain

  ⨯
• Pilar García-Alfonso,

  Affiliation Departamento de Oncologia Medica, Gregorio Marañon University Hospital, Madrid, Spain

  ⨯
• Meghna Alimchandani,

  Affiliation Center for Biologics Evaluation and Research, US Food and Drug Administration (USFDA), Silver Spring, Maryland, United States of America

  ⨯
• Markku Miettinen,

  Affiliation Laboratory of Pathology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland, United States of America

  ⨯
• Montserrat Blanco-Codesido,

  Affiliation Departamento de Oncologia Medica, Gregorio Marañon University Hospital, Madrid, Spain

  ⨯
• Tito Fojo

  Affiliation Division of Hematology and Oncology, Department of Medicine, Columbia University, New York and James J. Peters VA Medical Center, Bronx, New York, United States of America

  http://orcid.org/0000-0002-8083-2688

  ⨯